Insider Selling: Crispr Therapeutics AG (CRSP) Major Shareholder Sells 27,990 Shares of Stock

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 27,990 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $19.75, for a total value of $552,802.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $304,762.50.

Crispr Therapeutics AG (NASDAQ CRSP) traded up $2.23 on Friday, reaching $23.48. The company’s stock had a trading volume of 848,356 shares, compared to its average volume of 362,318. The firm has a market capitalization of $871.66, a P/E ratio of -17.79 and a beta of 5.70. Crispr Therapeutics AG has a 12-month low of $11.63 and a 12-month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter last year, the company earned ($2.77) earnings per share. analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current year.

Large investors have recently made changes to their positions in the company. Hershey Trust Co. acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at $768,000. Tiff Advisory Services Inc. acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at $505,000. Credit Suisse AG acquired a new stake in shares of Crispr Therapeutics during the 1st quarter valued at $1,742,000. Adams Street Partners LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at $1,019,000. Finally, Granahan Investment Management Inc. MA lifted its position in shares of Crispr Therapeutics by 51.7% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after acquiring an additional 89,839 shares during the last quarter. Institutional investors own 24.52% of the company’s stock.

A number of equities analysts recently issued reports on the company. Oppenheimer assumed coverage on Crispr Therapeutics in a report on Thursday, December 7th. They issued a “hold” rating for the company. Barclays reissued a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a report on Friday, September 8th. Piper Jaffray Companies initiated coverage on Crispr Therapeutics in a research report on Friday, December 22nd. They issued an “overweight” rating for the company. SunTrust Banks restated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $22.38.

WARNING: “Insider Selling: Crispr Therapeutics AG (CRSP) Major Shareholder Sells 27,990 Shares of Stock” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2017/12/30/corp-de-celgene-sells-27990-shares-of-crispr-therapeutics-ag-crsp-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply